Yunding Xinyao (01952.HK) receives exclusive license from Dimerix to develop and commercialize DMX-200 in Greater China, South Korea, and certain Southeast Asian countries.

Zhtng Cijng APP News, YunDing XinYo (01952.HK) announced that on June 16, 2026, the company entered into an agreement with Dimerix Limited (a company listed on the Australian Securities Exchange, stock code: DXB), whereby Dimerix irrevocably granted the company an exclusive license to develop and commercialize DMX-200 in Greater China, South Korea, and several Southeast Asian countries. DMX-200 is a small molecule inhibitor of the chemokine receptor 2 (CCR2) currently undergoing a critical Phase 3 clinical study, ACTION3, for focal segmental glomerulosclerosis (FSGS). DMX-200 has been granted orphan drug designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).